International: Eyestem Research Pvt. Ltd., a clinical-stage biotech company pioneering cell therapy for retinal diseases, announced successful Phase 1 trial results of its flagship therapy, Eyecyte-RPE™, at the 3rd China Great Bay Cell and Gene Therapy Forum (Innoxbio CGT 2025) in Guangzhou.

Dr. Jogin Desai, Founder & CEO of Eyestem, presented findings on “Safety and Efficacy of Eyecyte-RPE™ for Geographic Atrophy (GA) Secondary to Dry AMD.” The trial showed an average improvement of 14.8 letters in visual acuity at six months (8 subjects) and 13.3 letters at 12 months (4 subjects), with no treatment-related serious adverse events. These results highlight Eyecyte-RPE™’s potential to transform outcomes for patients with GA, a severe form of dry age-related macular degeneration (AMD).

Dr. Desai said, “Phase 1 demonstrates meaningful vision rescue with an excellent safety profile. As we plan Phase 2 in India and US trials in 2026, we aim to partner globally to make world-class, affordable cell therapies accessible to patients everywhere.”

Eyestem is also exploring licensing partnerships in China to advance local development and commercialization.